A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in…

Overview of attention for article published in International Journal of Gynecological Cancer, September 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news: 1 news outlet
twitter: 9 X users

facebook: 1 Facebook page

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 64,926 followers.

@StevenMusielski @Genelux_Corp The primary endpoint is progression free survival in the intention-to-treat population of patients with platinum-resistant/refractory ovarian cancer on platinum-based chemotherapy and bevacizumab. https://t.co/2A1kMifA9l

Thanks @IJGConline for covering this topic on #oncolytic #immunotherapy in platinum-resistant/refractory ovarian #cancer. Congratulations to our lead PI, Dr. Robert Holloway on the publication. Read the article: https://t.co/vKQ98ol8tS $GNLX #Stage4n…

RT @IJGConline: A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemo and #BEV compa…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.